5-Morpholino-pentanol-(1) | 4344-62-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 5-Morpholino-pentanol-(1)
• 英文别名: 5-(Morpholin-4-yl)pentan-1-ol；5-morpholin-4-ylpentan-1-ol
• CAS: 4344-62-1
• 化学式: C₉H₁₉NO₂
• 分子量: 173.255
• InChiKey: QXHSPHQXZGHRFK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.7
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  5-Morpholino-pentanol-(1) 在 sodium hydroxide 、 氯化亚砜 作用下， 生成 4-(5-[3]thienylmercapto-pentyl)-morpholine
  参考文献：
  名称：

  The Preparation and Properties of Some ι-(N,N-Dialkylamino) Alkyl-3-thienyl Sulfide Hydrochlorides¹

  摘要：

  DOI：

  10.1021/ja01105a015
• 作为产物：
  描述：

  4-吗啉戊腈 在 lithium aluminium tetrahydride 、 硫酸 作用下， 以 四氢呋喃 为溶剂， 生成 5-Morpholino-pentanol-(1)
  参考文献：
  名称：

  Talath, Sirajunisa; Gadad, Andanappa K., Arzneimittel-Forschung/Drug Research, 2006, vol. 56, # 11, p. 744 - 752

  摘要：

  DOI：

文献信息

• THIAZOLIDINONE COMPOUNDS AND USE THEREOF
  申请人：National Health Research Institutes

  公开号：US20170253569A1

  公开（公告）日：2017-09-07

  A pharmaceutical composition containing a compound of Formula (I) for treating an opioid receptor-associated condition. Also disclosed is a method for treating an opioid receptor-associated condition using such a compound. Further disclosed are two sets of thiazolidinone compounds of formula (I): (i) compounds each having an enantiomeric excess greater than 90% and (ii) compounds each being substituted with deuterium.

  一种含有化合物（I）的药物组合物，用于治疗与阿片受体相关的疾病。还公开了一种使用这种化合物治疗阿片受体相关疾病的方法。进一步公开了两组式（I）的噻唑烷酮化合物：（i）每种化合物的对映体过量大于90%；（ii）每种化合物被氘取代。
• Fused bicyclic amide compounds and medicinal use thereof
  申请人：——

  公开号：US20030203909A1

  公开（公告）日：2003-10-30

  The present invention provides a compound represented by the formula (I) 1 wherein ring A is benzene, cyclohexane, pyridine, piperidine or a derivative thereof, imidazole or a derivative thereof and the like, ring B is benzene, cyclohexane, pyrrole or a derivative thereof, furan, thiophene and the like, R 1 , R 2 and R 3 are each hydrogen, alkyl, halogen, hydroxyl group, alkoxy and the like, W is hydrogen, alkyl or hydroxycarbonylalkyl, X is halogen, cyano, nitro and the like, X′ is hydrogen, halogen and the like, and Y is alkyl, hydroxyalkyl, hydroxycarbonylalkyl, aminoalkyl and the like, a salt thereof, and a pharmaceutical agent containing the compound. The compound of the present invention shows a superior inhibitory effect on the proliferation of activated lymphocyte and is useful as an agent for the prophylaxis or treatment of various autoimmune diseases.

  本发明提供了一种由以下化学式（I）1所代表的化合物，其中环A为苯、环己烷、吡啶、哌啶或其衍生物、咪唑或其衍生物等，环B为苯、环己烷、吡咯或其衍生物、呋喃、噻吩等，R1、R2和R3分别为氢、烷基、卤素、羟基、烷氧基等，W为氢、烷基或羟基羰基烷基，X为卤素、氰基、硝基等，X′为氢、卤素等，Y为烷基、羟基烷基、羟基羰基烷基、氨基烷基等，其盐和含有该化合物的药物。本发明的化合物对活化淋巴细胞的增殖具有优越的抑制作用，并可用作各种自身免疫性疾病的预防或治疗剂。
• METHOD OF MAKING MONOMETHYL FUMARATE
  申请人：XenoPort, Inc.

  公开号：US20140364604A1

  公开（公告）日：2014-12-11

  Methods of making monomethyl fumarate, which can then also be used in methods of making prodrugs of monomethyl fumarate, are disclosed. Monomethyl fumarate and prodrugs of monomethyl fumarate are useful for treating neurodegenerative, inflammatory, and autoimmune diseases including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis.

  公开了制备单甲基富马酸的方法，该单甲基富马酸随后也可用于制备单甲基富马酸的前药的方法。单甲基富马酸及其前药可用于治疗神经退行性、炎症性和自身免疫性疾病，包括多发性硬化、银屑病、肠易激综合征、溃疡性结肠炎、关节炎、慢性阻塞性肺疾病、哮喘、帕金森病、亨廷顿病和肌萎缩侧索硬化症。
• PROCESS FOR PREPARING TETRAMETHYL GLYCOLIDE
  申请人：Vogel Bernd

  公开号：US20100010276A1

  公开（公告）日：2010-01-14

  The present invention relates to a process for preparing tetramethylglycolide by heating a composition which comprises at least 50% by weight of 2-hydroxy-isobutyric acid and/or tetramethylglycolide to a temperature of at least 100° C.

  本发明涉及一种制备四甲基乙二酰乙酯的方法，包括将含有至少50%重量的2-羟基异丁酸和/或四甲基乙二酰乙酯的组合物加热至至少100℃的温度。
• 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION
  申请人：OHTAKE Yasuhiro

  公开号：US20080076760A1

  公开（公告）日：2008-03-27

  The present invention has its object to provide a 2,3,4,5-tetrahydro-1H-1,5-benzodiazepine derivative represented with the Formula (1) or the pharmaceutically acceptable salt, which is effective as a therapeutic and prophylactic agent for diabetes, diabetic nephropathy, or glomerulosclerosis.

  本发明旨在提供一种以公式（1）表示的2,3,4,5-四氢-1H-1,5-苯并二氮平衍生物或其药学上可接受的盐，该化合物可作为治疗和预防糖尿病、糖尿病肾病或肾小球硬化的药物。